Mike Henderson
@mxhend.bsky.social
200 followers 350 following 6 posts
Associate Professor Van Andel Institute Focused on neurodegeneration, synuclein, tau
Posts Media Videos Starter Packs
mxhend.bsky.social
Another graduate student defended! Congratulations, Dr. Goralski!
hndlab.bsky.social
Congratulations to Dr. Goralski on a fantastic dissertation defense! The whole lab showed up in Tommy's usual attire to celebrate with him! @vai.org #PhD
mxhend.bsky.social
#proudmentor
hndlab.bsky.social
Excited to celebrate the graduation of our first PhD student, Dr. Alysa Kasen!!!
Reposted by Mike Henderson
mrclmb.bsky.social
Excellent opportunity for a postdoc to join @sjorsscheres.bsky.social in the LMB’s Structural Studies Division to work on #cryoEM structure determination of amyloid filaments in a lively, multi-disciplinary group.
Read more: www.nature.com/naturecareer...
Closes 03 AUG
#PostdocJobs #ScienceJobs
Sjors Scheres
mxhend.bsky.social
Excited to have several new lab members join us this year!
hndlab.bsky.social
It’s been a busy year so far in the Henderson lab! We have several new lab members to welcome—Anika and Noah as new graduate students, Aastha as a new postdoc, Sydney as a new technician, and Giang, Kelsey, and @abbeyzuzelski.bsky.social who are joining us as summer fellows! The lab is bustling!
mxhend.bsky.social
Congratulations to grad student Ben for passing his qualifying exam! Now he gets to do all the exciting research he has proposed!
mxhend.bsky.social
Great collaboration with @sjorsscheres.bsky.social led by graduate student @alysa-kasen.bsky.social! It turns out core filament structure and fuzzy coat PTMs contribute to tau seeding.
mxhend.bsky.social
Another first place poster prize for graduate student @alysa-kasen.bsky.social for her work on tau pathology seeding! She is finishing up this summer and looking for a postdoc if anyone needs an excellent scientist!
Reposted by Mike Henderson
scienceofpd.bsky.social
Pharmaceutical company Roche announce that their Phase IIb PADOVA study of the alpha synuclein targeting antibody Prasinezumab just missed its primary endpoint (p=0.0657), but their data suggests possible clinical benefit in early-stage #Parkinsons
www.roche.com/media/releas...
Reposted by Mike Henderson
hndlab.bsky.social
Henderson Lab winter party 2024! Happy holidays everyone!